The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism

Pharmacology and Therapeutics

Volumn 130, Issue 1, 2011, Pages 46-58

  Mavrakanas, Thomas ^a   Bounameaux, Henri ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran etexilate; Edoxaban; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 79951853381     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.12.007     Document Type: Review

References (96)

1. G. Agnelli, A. Gallus, S.Z. Goldhaber, S. Haas, M.V. Huisman, and R.D. Hull Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study Circulation 116 2007 180 187 (Pubitemid 47057524)
2. G.W. Albers, H.C. Diener, L. Frison, M. Grind, M. Nevinson, and S. Partridge Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial JAMA 293 2005 690 698
3. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 160S 198S (Pubitemid 351892967)
4. W.L. Baker, D.A. Cios, S.D. Sander, and C.I. Coleman Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244 252
5. K.A. Bauer New anticoagulants: Anti IIa vs anti Xa-Is one better? J Thromb Thrombolysis 21 2006 67 72 (Pubitemid 43231131)
6. ® (rivaroxaban) Summary of Product Characteristics 2009 Available at: http://www.xarelto.com/html/ downloads/Xarelto-Summary -of- Product-Characteristics-May2009.pdf [accessed 11-11-2010]
7. A. Biondi, G. Strano, L. Ruggeri, S. Vadala, A. Tropea, and F. Basile Clinical biomarkers and management of post thrombotic syndrome Front Biosci (Elite Ed) 2 2010 771 778
8. ® (dabigatran etexilate) Summary of Product Characteristics 2009 Available at: http://www.pradaxa.com/Include/media/pdf/Pradaxa-SPC-EMEA.pdf [accessed 19-10-2010]
9. H. Bounameaux The novel anticoagulants: Entering a new era Swiss Med Wkly 139 2009 60 64
10. H. Bounameaux, and G. Reber New oral antithrombotics: A need for laboratory monitoring. Against J Thromb Haemost 8 2010 627 630
11. H.R. Büller, J.L. Halperin, H. Bounameaux, and M. Prins Double-blind studies are not always optimum for evaluation of a novel therapy: The case of new anticoagulants J Thromb Haemost 6 2008 227 229
12. H.R. Buller, A.W. Lensing, M.H. Prins, G. Agnelli, A. Cohen, and A.S. Gallus A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study Blood 112 2008 2242 2247
13. J. Carreiro, and J. Ansell Apixaban, an oral direct Factor Xa inhibitor: Awaiting the verdict Expert Opin Investig Drugs 17 2008 1937 1945
14. A.T. Cohen, G. Agnelli, F.A. Anderson, J.I. Arcelus, D. Bergqvist, and J.G. Brecht Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality Thromb Haemost 98 2007 756 764 (Pubitemid 47555066)
15. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
16. S.J. Connolly, M. Ezekowitz, S. Yusuf, P.A. Reilly, L. Wallentin for the RE-LY Investigators Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
17. F. Depasse, J. Busson, J. Mnich, L. Le Flem, G.T. Gerotziafas, and M.M. Samama Effect of BAY 59-7939-A novel, oral, direct Factor Xa inhibitor-On clot-bound Factor Xa activity in vitro J Thromb Haemost 3 Suppl. 1 2005 Abstract P1104
18. A. Diamantopoulos, M. Lees, P.S. Wells, F. Forster, J. Ananthapavan, and H. McDonald Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada Thromb Haemost 104 2010 760 770
19. J.W. Eikelboom, M. O'Donnell, S. Yusuf, R. Diaz, G. Flaker, and R. Hart Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 159 2010 348 353
20. EINSTEIN Investigators, Bauersachs, R., Berkowitz, S. D., Brenner, B., Buller, H. R., Decousus H., et al. (2010). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363, 2499-2510.
21. W.G. Eisert, N. Hauel, J. Stangier, W. Wienen, A. Clemens, and J. van Ryn Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin Arterioscler Thromb Vasc Biol 30 2010 1885 1889
22. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
23. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
24. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956 (Pubitemid 47393577)
25. J.N. Fiessinger, M.V. Huisman, B.L. Davidson, H. Bounameaux, C.W. Francis, and H. Eriksson Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial JAMA 293 2005 681 689 (Pubitemid 40216038)
26. C.W. Francis, S.D. Berkowitz, P.C. Comp, J.R. Lieberman, J.S. Ginsberg, and G. Paiement Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 2003 1703 1712 (Pubitemid 37315007)
27. C. Frost, Z. Yu, K. Moore, S. Nepal, R. Barrett, and R. Mosqueda-Garcia Apixaban, an oral direct factor Xa inhibitor: Multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects J Thromb Haemost 5 Suppl. 2 2007 Abstract P-M-664
28. T. Fuji, S. Fujita, S. Tachibana, and Y. Kawai A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty J Thromb Haemost 8 2010 2458 2468
29. T. Fuji, C.J. Wang, S. Fujita, S. Tachibana, and Y. Kawai Edoxaban in patients undergoing total hip arthroplasty: A phase IIb dose-finding study Blood (ASH Annual Meeting Abstracts) 114 2009 827 Abstract 2098
30. C.D. Furberg, and E.Z. Soliman Double-blindness protects scientific validity J Thromb Haemost 6 2008 230 231
31. T. Furugohri, K. Isobe, Y. Honda, C. Kamisato-Matsumoto, N. Sugiyama, and T. Nagahara DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles J Thromb Haemost 6 2008 1542 1549
32. B.F. Gage Can we rely on RE-LY? N Engl J Med 361 2009 1200 1202
33. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 381S 453S (Pubitemid 351894916)
34. E. Ginzburg, and F. Dujardin Physicians' perceptions of the definition of major bleeding in major orthopedic surgery: Results of an international survey J Thromb Thrombolysis 31 2010 188 195
35. S. Haas New oral Xa and IIa inhibitors: Updates on clinical trial results J Thromb Thrombolysis 25 2008 52 60
36. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867 (Pubitemid 351650486)
37. J.A. Heit, A.T. Cohen, F.A. Anderson on behalf of the VTE Impact Assessment Group Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US Blood (ASH Annual Meeting Abstracts) 106 2005 Abstract 910
38. J. Hirsh, K.A. Bauer, M.B. Donati, M. Gould, M.M. Samama, and J.I. Weitz Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 141S 159S (Pubitemid 351892966)
39. J. Hirsh, T.E. Warkentin, R. Raschke, C. Granger, E.M. Ohman, and J.E. Dalen Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety Chest 114 1998 489S 510S (Pubitemid 28535777)
40. X. Jiang, E.J. Crain, J.M. Luettgen, W.A. Schumacher, and P.C. Wong Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro Thromb Haemost 101 2009 780 782
41. S.R. Kahn Frequency and determinants of the postthrombotic syndrome after venous thromboembolism Curr Opin Pulm Med 12 2006 299 303 (Pubitemid 44315771)
42. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial Lancet 372 2008 31 39
43. C. Kearon, S.R. Kahn, G. Agnelli, S. Goldhaber, G.E. Raskob, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 454S 545S (Pubitemid 351892971)
44. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-An oral, direct Factor Xa inhibitor-Are not affected by aspirin J Clin Pharmacol 46 2006 981 990 (Pubitemid 44215062)
45. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin J Clin Pharmacol 46 2006 702 Abstract 11
46. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Rivaroxaban (BAY 59-7939)-An oral, direct Factor Xa inhibitor-Has no clinically relevant interaction with naproxen Br J Clin Pharmacol 63 2007 469 476 (Pubitemid 46426627)
47. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Co-administration of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-And clopidogrel in healthy subjects Eur Heart J 28 Suppl. 1 2007 189 Abstract P1272
48. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor Clin Pharmacol Ther 78 2005 412 421 (Pubitemid 41393676)
49. D. Kubitza, and S. Haas Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases Expert Opin Investig Drugs 15 2006 843 855 (Pubitemid 44177839)
50. D. Kubitza, W. Mueck, and M. Becka No interaction between rivaroxaban-A novel, oral, direct factor Xa inhibitor-And atorvastatin Pathophysiol Haemost Thromb 36 2008 A40
51. R. Kumar, S. Beguin, and H.C. Hemker The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity Thromb Haemost 74 1995 962 968
52. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786 (Pubitemid 351930852)
53. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial Lancet 375 2010 807 815
54. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: The ADVANCE-3 trial Pathophysiol Haemost Thromb 37 2010 A20 Abstract OC356
55. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
56. V. Laux, E. Perzborn, S. Heitmeier, G. von Degenfeld, E. Dittrich-Wengenroth, and A. Buchmuller Direct inhibitors of coagulation proteins-The end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 102 2009 892 899
57. D.M. Lloyd-Jones, T.J. Wang, E.P. Leip, M.G. Larson, D. Levy, and R.S. Vasan Lifetime risk for development of atrial fibrillation: The Framingham Heart Study Circulation 110 2004 1042 1046 (Pubitemid 39319000)
58. R.D. Lopes, J.H. Alexander, S.M. Al Khatib, J. Ansell, R. Diaz, and J.D. Easton Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale Am Heart J 159 2010 331 339
59. K.G. Mann The biochemistry of coagulation Clin Lab Med 4 1984 207 220 (Pubitemid 14028137)
60. K.G. Mann, K. Brummel, and S. Butenas What is all that thrombin for? J Thromb Haemost 1 2003 1504 1514
61. L. McCullagh, L. Tilson, C. Walsh, and M. Barry A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting Pharmacoeconomics 27 2009 829 846
62. Y. Morishima, T. Furugohri, K. Isobe, Y. Honda, C. Matsumoto, and Y. Shiozaki In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b Blood (ASH Annual Meeting Abstracts) 104 2004 Abstract 1862
63. W. Mueck, M. Becka, D. Kubitza, B. Voith, and M. Zuehlsdorf Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-An oral, direct Factor Xa inhibitor-In healthy subjects Int J Clin Pharmacol Ther 45 2007 335 344 (Pubitemid 46895052)
64. K. Ogata, J. Mendell-Harary, M. Tachibana, H. Matsumoto, T. Oguma, and M. Kojima Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
65. S.B. Olsson, L.H. Rasmussen, A. Tveit, E. Jensen, P. Wessman, and S. Panfilov Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation Thromb Haemost 103 2010 604 612
66. M. Patel, R. Becker, G. Breithardt, W. Hacke, J. Halperin, and G. Hankey Rationale and design of the ROCKET AF study: Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation Eur Heart J 30 2009 705 Abstract P4198
67. V. Pengo, A.W. Lensing, M.H. Prins, A. Marchiori, B.L. Davidson, and F. Tiozzo Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism N Engl J Med 350 2004 2257 2264
68. E. Perzborn Factor Xa inhibitors-New anticoagulants for secondary haemostasis Hamostaseologie 29 2009 260 267
69. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-An oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521 (Pubitemid 41632877)
70. R. Pesavento, E. Bernardi, A. Concolato, F. Dalla Valle, A. Pagnan, and P. Prandoni Postthrombotic syndrome Semin Thromb Hemost 32 2006 744 751 (Pubitemid 44623383)
71. D.J. Pinto, M.J. Orwat, S. Koch, K.A. Rossi, R.S. Alexander, and A. Smallwood Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4, 5, 6, 7-tetrahydro- 1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation Factor Xa J Med Chem 50 2007 5339 5356 (Pubitemid 350057846)
72. P. Prandoni, A.W.A. Lensing, A. Cogo, S. Cuppini, S. Villalta, and M. Carta The long-term clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1 7
73. N. Raghavan, C.E. Frost, Z. Yu, K. He, H. Zhang, and W.G. Humphreys Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 2009 74 81
74. G. Raskob, A.T. Cohen, B.I. Eriksson, D. Puskas, M. Shi, and T. Bocanegra Oral direct Factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study Thromb Haemost 104 2010 642 649
75. C.T. Ruff, R.P. Giugliano, E.M. Antman, S.E. Crugnale, T. Bocanegra, and M. Mercuri Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
76. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
77. S. Schulman, K. Wåhlander, T. Lundström, S.B. Clason, H. Eriksson THRIVE III Investigators Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran N Engl J Med 349 2003 1713 1721 (Pubitemid 37315008)
78. E. Shantsila, and G.Y. Lip Apixaban, an oral, direct inhibitor of activated Factor Xa Curr Opin Investig Drugs 9 2008 1020 1033
79. D.E. Singer, G.W. Albers, J.E. Dalen, A.S. Go, J.L. Halperin, and W.J. Manning Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 429S 456S (Pubitemid 39302603)
80. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295 (Pubitemid 351508116)
81. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
82. J. Stangier, K. Rathgen, H. Stahle, K. Reseski, T. Kornicke, and W. Roth Coadministration of dabigatran etexilate and atorvastatin: Assessment of potential impact on pharmacokinetics and pharmacodynamics Am J Cardiovasc Drugs 9 2009 59 68
83. L. Testa, F. Andreotti, G.G. Biondi Zoccai, F. Burzotta, F. Bellocci, and F. Crea Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22, 639 patients Int J Cardiol 122 2007 117 124 (Pubitemid 47559087)
84. The RE-MOBILIZE Writing Committee The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
85. A.G.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial Lancet 373 2009 1673 1680
86. M. Ufer Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development Thromb Haemost 103 2010 572 585
87. R. Varin, S. Mirshahi, P. Mirshahi, J. Chidiac, G. Kierzek, and J.P. Marie Effect of rivaroxaban, an oral direct Factor Xa inhibitor, on whole blood clot permeation and thrombolysis: Critical role of red blood cells Blood (ASH Annual Meeting Abstracts) 114 2009 Abstract 1064
88. J.I. Weitz New oral anticoagulants in development Thromb Haemost 103 2010 62 70
89. J.I. Weitz, and S.M. Bates New anticoagulants J Thromb Haemost 3 2005 1843 1853 (Pubitemid 41716571)
90. J.I. Weitz, J. Hirsh, and M.M. Samama New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 234S 256S (Pubitemid 351892968)
91. J.I. Weitz, S.J. Connolly, S. Kunitada, J. Jin, and I. Patel Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation Blood (ASH Annual Meeting Abstracts) 112 2008 Abstract 33
92. J.I. Weitz, M. Hudoba, D. Massel, J. Maraganore, and J. Hirsh Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Invest 86 1990 385 391 (Pubitemid 20271869)
93. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: The Framingham Study Stroke 22 1991 983 988
94. P.C. Wong, E.J. Crain, B. Xin, R.R. Wexler, P.Y. Lam, and D.J. Pinto Apixaban, an oral, direct and highly selective Factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies J Thromb Haemost 6 2008 820 829 (Pubitemid 351524543)
95. M.U. Zafar, D.A. Vorchheimer, J. Gaztanaga, M. Velez, D. Yadegar, and P.R. Moreno Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber Thromb Haemost 98 2007 883 888 (Pubitemid 47555083)
96. T. Zhu, I. Martinez, and J. Emmerich Venous thromboembolism: Risk factors for recurrence Arterioscler Thromb Vasc Biol 29 2009 298 310